Developmental changes of apolipoprotein E immunoreactivity in Down syndrome brains. 1995

Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
Department of Mental Retardation and Birth Defect Research, National Center for Neurology and Psychiatry, Tokyo, Japan.

The temporal profile of apolipoprotein-E (apo-E) expression was investigated immunohistochemically in the brains of Down syndrome patients and of normal controls. The number of apo-E immunoreactive astrocytes in the frontal cortex was larger in Down syndrome patients than in controls from 7 months to 24 years of age. It suggests that apo-E producing astrocytes in the early phase of pathological process lead to presenile dementia in Down syndrome patients. In contrast, the number in the white matter was smaller in Down syndrome patients from 28 gestational weeks to 5 years. Apo-E immunoreactive senile plaques were noted in Down syndrome brains from the age of 25 years, while APP immunoreactivity was first noted in senile plaques at the age of 32 years.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004314 Down Syndrome A chromosome disorder associated either with an extra CHROMOSOME 21 or an effective TRISOMY for chromosome 21. Clinical manifestations include HYPOTONIA, short stature, BRACHYCEPHALY, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, single transverse palmar crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213) Mongolism,Trisomy 21,47,XX,+21,47,XY,+21,Down Syndrome, Partial Trisomy 21,Down's Syndrome,Partial Trisomy 21 Down Syndrome,Trisomy 21, Meiotic Nondisjunction,Trisomy 21, Mitotic Nondisjunction,Trisomy G,Downs Syndrome,Syndrome, Down,Syndrome, Down's
D005314 Embryonic and Fetal Development Morphological and physiological development of EMBRYOS or FETUSES. Embryo and Fetal Development,Prenatal Programming,Programming, Prenatal
D005333 Fetus The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN. Fetal Structures,Fetal Tissue,Fetuses,Mummified Fetus,Retained Fetus,Fetal Structure,Fetal Tissues,Fetus, Mummified,Fetus, Retained,Structure, Fetal,Structures, Fetal,Tissue, Fetal,Tissues, Fetal

Related Publications

Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
May 2016, Aging and disease,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
September 1997, Pediatric neurology,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
January 1999, Journal of neural transmission. Supplementum,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
January 1990, Brain & development,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
December 2020, Journal of clinical medicine,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
May 1999, Neuroscience letters,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
September 1994, Rinsho byori. The Japanese journal of clinical pathology,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
May 1997, Neuroreport,
Y Arai, and M Mizuguchi, and K Ikeda, and S Takashima
January 1985, International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience,
Copied contents to your clipboard!